1. Bleyer A, O'Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age: including SEER incidence and survival: 1975??000. Bethesda (MD): U.S. Department of Health and Human Services, National Institutes of Health; 2006.
2. Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, et al. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2012;10:1112-1150. PMID:
22956810.
5. Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931. PMID:
16651642.
6. Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2013;31:2500-2510. PMID:
23715580.
7. Japan Society of Clinical Oncology. JSCO clinical practice guidelines 2017 for fertility preservation in childhood, adolescent and young adult cancer patients. Tokyo: Japan Society of Clinical Oncology; 2017. in Japanese.
8. Practice Committees of American Society for Reproductive Medicine. Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37-43. PMID:
23083924.
9. Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril 2013;100:1673-1680. PMID:
23987516.
10. Reddy J, Turan V, Bedoschi G, Moy F, Oktay K. Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience. J Assist Reprod Genet 2014;31:927-932. PMID:
24854484.
11. Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast cancer. J Clin Oncol 2015;33:2424-2429. PMID:
26101247.
12. Japan Society of Obstetrics and Gynecology. Views on unfertilized oocytes, embryos and ovarian tissues freezing and preservation by medical adaptation. Acta Obstet Gynaecol Jpn 2016;68:1470-1474.
13. Oktay K, Karlikaya G. Ovarian function after transplantation of frozen, banked autologous ovarian tissue. N Engl J Med 2000;342:1919.
14. Donnez J, Dolmans MM, Demylle D, Jadoul P, Pirard C, Squifflet J, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-1410. PMID:
15488215.
15. von Wolff M, Dittrich R, Liebenthron J, Nawroth F, Schüring AN, Bruckner T, et al. Fertility-preservation counselling and treatment for medical reasons: data from a multinational network of over 5000 women. Reprod Biomed Online 2015;31:605-612. PMID:
26380870.
16. Practice Committee of American Society for Reproductive Medicine. Ovarian tissue cryopreservation: a committee opinion. Fertil Steril 2014;101:1237-1243. PMID:
24684955.
17. Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet 2017;34:325-336. PMID:
28028773.
18. Suzuki N. Ovarian tissue cryopreservation using vitrification and/or
in vitro activated technology. Hum Reprod 2015;30:2461-2462. PMID:
26345682.
19. Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, et al. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. Hum Reprod 2015;30:608-615. PMID:
25567618.
20. Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci USA 2013;110:17474-17479. PMID:
24082083.
21. Shi Q, Xie Y, Wang Y, Li S. Vitrification versus slow freezing for human ovarian tissue cryopreservation: a systematic review and meta-anlaysis. Sci Rep 2017;7:8538PMID:
28819292.
22. Kawahara T, Sugishita Y, Taylan E, Suzuki N, Moy F, Oktay KH. Vitrification versus slow freezing of human ovarian tissue: a comparison of follicle survival and DNA damage. Fertil Steril 2017;108:e56-e57.
23. Sugishita Y, Taylan E, Kawahara T, Suzuki N, Oktay KH. Comparison of open and closed devices in human ovarian tissue vitrification. Fertil Steril 2017;108:e172-e173.
24. Takae S, Tsukada K, Sato Y, Okamoto N, Kawahara T, Suzuki N. Accuracy and safety verification of ovarian reserve assessment technique for ovarian tissue transplantation using optical coherence tomography in mice ovary. Sci Rep 2017;7:43550PMID:
28272468.
25. Dolmans MM, Marinescu C, Saussoy P, Van Langendonckt A, Amorim C, Donnez J. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood 2010;116:2908-2914. PMID:
20595517.
26. Greve T, Clasen-Linde E, Andersen MT, Andersen MK, Sørensen SD, Rosendahl M, et al. Cryopreserved ovarian cortex from patients with leukemia in complete remission contains no apparent viable malignant cells. Blood 2012;120:4311-4316. PMID:
22709693.
27. Dolmans MM, Luyckx V, Donnez J, Andersen CY, Greve T. Risk of transferring malignant cells with transplanted frozen-thawed ovarian tissue. Fertil Steril 2013;99:1514-1522. PMID:
23541406.
28. Hoekman EJ, Smit VT, Fleming TP, Louwe LA, Fleuren GJ, Hilders CG. Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach. Fertil Steril 2015;103:469-477. PMID:
25497447.
29. Donnez J, Dolmans MM, Pellicer A, Diaz-Garcia C, Ernst E, Macklon KT, et al. Fertility preservation for age-related fertility decline. Lancet 2015;385:506-507.
30. Wallace WH, Smith AG, Kelsey TW, Edgar AE, Anderson RA. Fertility preservation for girls and young women with cancer: population-based validation of criteria for ovarian tissue cryopreservation. Lancet Oncol 2014;15:1129-1136. PMID:
25130994.
31. Sugishita Y, Hashimoto S, Hoshina M, Kawagoe Y, Yoshioka N, Takae S, et al. Ovarian tissue vitrification: ovarian tissue cryopreservation and transplantation. Ishiyakushuppan 2017 7:46-59. (in Japanese).
32. Takae S, Sugishita Y, Yoshioka N, Hoshina M, Horage Y, Sato Y, et al. The role of menstrual cycle phase and AMH levels in breast cancer patients whose ovarian tissue was cryopreserved for oncofertility treatment. J Assist Reprod Genet 2015;32:305-312. PMID:
25464895.
33. Xiao S, Duncan FE, Bai L, Nguyen CT, Shea LD, Woodruff TK. Size-specific follicle selection improves mouse oocyte reproductive outcomes. Reproduction 2015;150:183-192. PMID:
26116002.
34. Ataya K, Rao LV, Lawrence E, Kimmel R. Luteinizing hormone-releasing hormone agonist inhibits cyclophosphamide-induced ovarian follicular depletion in rhesus monkeys. Biol Reprod 1995;52:365-372. PMID:
7711205.
35. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-276. PMID:
21771987.
36. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival, a randomized clinical trial. JAMA 2015;314:2632-2640. PMID:
26720025.
37. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-538. PMID:
22231041.
38. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-2341. PMID:
21537042.
39. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923-932. PMID:
25738668.
40. Demeestere I, Brice P, Peccatori FA, Kentos A, Dupuis J, Zachee P, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol 2016;34:2568-2574. PMID:
27217453.
41. Munhoz RR, Pereira AA, Sasse AD, Hoff PM, Traina TA, Hudis CA, et al. Gonadotropin-releasing hormone agonists for ovarian function preservation in premenopausal women undergoing chemotherapy for early-stage breast cancer: a systematic review and meta-analysis. JAMA Oncol 2016;2:65-73. PMID:
26426573.
42. Oktay K, Turan V. Failure of ovarian suppression with gonadotropin-releasing hormone analogs to preserve fertility: an assessment based on the quality of evidence. JAMA Oncol 2016;2:74-75. PMID:
26426406.
43. Coccia PF, Pappo AS, Altman J, Bhatia S, Borinstein SC, Flynn J, et al. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw 2014;12:21-32. PMID:
24453290.
44. Moss JL, Choi AW, Fitzgerald Keeter MK, Brannigan RE. Male adolescent fertility preservation. Fertil Steril 2016;105:267-273. PMID:
26707904.
45. Gupta AA, Donen RM, Sung L, Boydell KM, Lo KC, Stephens D, et al. Testicular biopsy for fertility preservation in prepubertal boys with cancer. Identifying preferences for procedure and reactions to disclosure practices. J Urol 2016;196:219-224. PMID:
26947434.
46. Long CJ, Ginsberg JP, Kolon TF. Fertility preservation in children and adolescents with cancer. Urology 2016;91:190-196. PMID:
26790587.
47. Woodruff TK. The emergence of a new interdiscipline: oncofertility. Cancer Treat Res 2007;138:3-11. PMID:
18080653.